Table 3 Correlations between the clinicopathological factors and estrogen receptors (ERa, ERb)
From: GPR30 regulates the EGFR-Akt cascade and predicts lower survival in patients with ovarian cancer
Variables | Expression of ERĪ± | p value | Expression of ERĪ² | p value | ||
|---|---|---|---|---|---|---|
| Ā | Positive | Negative | Ā | Positive | Negative | Ā |
Age | 55.9 Ā±13.1 | 52.6Ā±13.1 | 0.12 | 55.8 Ā±12.3 | 53.6Ā±11.9 | 0.37 |
āPremenopausal | 24 (36.4%) | 42 (63.6%) | 0.24 | 16 (24.2%) | 50 (75.8%) | 0.85 |
āPostmenopausal | 41 (42.7%) | 55 (57.3%) | Ā | 20 (20.8%) | 76 (79.2%) | Ā |
BMI | 22.3 Ā±2.5 | 21.7 Ā±2.6 | 0.24 | 21.7 Ā± 4.5 | 22.0 Ā± 2.9 | 0.75 |
Borderline malignancy | 5 (50.0%) | 5 (50.0%) | 0.72 | 6 (60.0%) | 4 (40.0%) | 0.08 |
FIGO stage I | 10 (25.6%) | 29 (74.4%) | 0.99 | 14 (35.9%) | 25 (64.1%) | 0.06 |
āāāāāII | 9 (64.3%) | 5 (35.7%) | Ā | 2 (14.3 %) | 12 (85.7%) | Ā |
āāāāāIII | 34 (44.2%) | 43 (55.8%) | Ā | 14 (18.2%) | 63 (81.8%) | Ā |
āāāāāIV | 7 (31.8%) | 15 (68.2%) | Ā | 0 (0%) | 22 (100%) | Ā |
Histology | Ā | Ā | Ā | Ā | Ā | Ā |
āBorderline malignancy | 5 (50.0%) | 5 (50.0%) | 0.72 | 6 (60.0%) | 4 (40.0%) | 0.08 |
āSerous adenocarcinoma | 32 (52.5%) | 29 (47.5%) | 0.004 | 11 (18.0%) | 50 (82.0%) | 0.14 |
āEndometrioid adenocarcinoma | 16 (53.3%) | 14 (46.7%) | Ā | 4 (13.8%) | 26 (86.2%) | Ā |
āMucinous adenocarcinoma | 5 (26.3%) | 14 (73.7%) | Ā | 8 (42.1%) | 11 (57.9%) | Ā |
āClear cell adenocarcinoma | 3 (10.3%) | 26 (89.7%) | Ā | 6 (20.7%) | 23 (79.3%) | Ā |
āOthers | 4 (30.8%) | 9 (69.2%) | Ā | 1 (7.7%) | 12 (92.3%) | Ā |
Recurrence | Ā | Ā | 0.14 | Ā | Ā | 0.06 |
āā¤ 6M | 8 (42.1%) | 11 (57.9%) | Ā | 4 (21.1%) | 15 (78.9%) | Ā |
ā> 6M | 31 (48.4%) | 33 (51.6%) | Ā | 10 (15.6%) | 54 (84.4%) | Ā |
āNo recurrence | 26 (32.9%) | 53 (67.1%) | Ā | 22 (27.8%) | 57 (72.2%) | Ā |
5-year survival | Ā | Ā | 0.47 | Ā | Ā | 0.06 |
āAlive | 41 (40.2%) | 61 (59.8%) | Ā | 26 (25.4%) | 76 (74.6%) | Ā |
āDead | 24 (40.0%) | 36 (60.0%) | Ā | 10 (16.7%) | 50 (83.3%) | Ā |